106 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Interim Analysis of the Multinational, Prospective, Noninterventional Study ELEANOR (N=300)
ByReshma L. Mahtani, DO ,Diana Lüftner,Denise Wrobel,Dagmar Guth,Matthias Zaiss,Jürgen Terhaag,Mark-Oliver Zahn,Lidia Pervola-Griff,Andrea Distelrath,Rachel Würstlein,Jörg Thomalla,Klaus Apel,Natalija Deuerling,Timo Schinköthe,Corinne Vannier,Rupert Bartsch,Christian Jackisch,Volkmar Müller,Marcus Schmidt,Marija Balic,Gabriel Rinnerthaler,Urs Breitenstein,Khalil Zaman,Michael Schwitter,Nadia Harbeck, MD, PhD